Caladrius Biosciences, Inc. (CLBS) has seen some recent movement in the market and its shares were last quoted at $2.1600 yesterday. Investors are starting to take notice of CLBS as the shares traded as high as $2.2800 and as low as $2.0000 in the previous market trading session.
Caladrius Biosciences, Inc. (CLBS) average trading volume is 89.14K. However, in the previous market trading session Caladrius Biosciences, Inc. (CLBS) exchanged 471,263 shares. The first support level on CLBS is $2.08 and the first upside resistance level on CLBS is $3.58. CLBS 50 day moving average is $2.0094 and CLBS 200 day moving average is $2.4213.
Caladrius Biosciences, Inc. (CLBS) recent performance has been specified by the recent movement in CLBS shares. CLBS has performed -4.85% over the past month, CLBS has performed -21.45% over the past quarter and CLBS has shown -28.24% over the past 12 months. Caladrius Biosciences, Inc. (CLBS) has a 12 month range of $1.0500 to $3.6400. Caladrius Biosciences, Inc. (CLBS) is trading 105.71% from its 12 month low and -40.66% from its 12 month high. Caladrius Biosciences, Inc. (CLBS) is indicating a 0.06% short float indicating the amount short in the float.
CLBS has 12.03M shares outstanding and 11.40M shares in the float. Caladrius Biosciences, Inc. (CLBS) at this time has a market cap of $25.98M and income of $-19.40M. The EPS next quarter for CLBS is -0.30 and forecasted EPS net year is 63.30%. The market cap of Caladrius Biosciences, Inc. (CLBS) at $25.98M signifies how many Investors own shares of CLBS and is calculated off the last price ($2.1600) of CLBS and the amount of shares outstanding (12.03M) with Caladrius Biosciences, Inc. (CLBS).
Caladrius Biosciences, Inc. (CLBS) has total cash (mrq) of 20.75M, total cash per share (mrq) of 1.95. Caladrius Biosciences, Inc. (CLBS) running cash flow (ttm) is -17.64M and CLBS leveraged free cash flow (ttm) is -10.23M. CLBS is trading 2.78% above (bullish) its SMA20, 8.42% above (bullish) its SMA50 and -11.34% below (bearish) its SMA200.
Recent News:
In recent news, on May 7, 2020, it stated, Company initiates development of CLBS119 for the repair of COVID-19 induced lung damage and expands its proprietary CD34+ cell therapy portfolio Adds ~$16 million in funding bringing current cash to ~$34 million
About Caladrius Biosciences, Inc. (CLBS):
Caladrius Biosciences, Inc. is an immunotherapy company which specializes in cell process optimization, development and manufacturing. Its product candidate consists of NBS20, a targeted cancer immunotherapy product for the treatment of metastatic melanoma; NBS10, an ischemic repair product to preserve heart muscle function following an acute myocardial infarction and NBS03D, an immune modulation product for the treatment of diabetes which are in different clinical trials.
